It was a delight to catch up with our Expert Faculty Member, Dr Gil Y Melmed (Cedars-Sinai Medical Center, Los Angeles, CA, US), to discuss the recent phase 2 and 3 analyses of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib.
His abstract entitled ‘Herpes Zoster Infection in Patients with Ulcerative Colitis Receiving tofacitinib results from the Phase 2 and Phase 3 Clinical Programs’ (Fr5340) was presented at DDW, 21-23 May 2021.
- What has the tofacitinib UC clinical trial program taught us about the herpes zoster incidence during the induction and maintenance treatment of ulcerative colitis with tofacitinb? (0:17)
- Could you tell us a little about the analysis you presented at the Digestive Disease Week® (DDW) meeting, and its findings? (1:19)
- Which patients have the highest risk of herpes zoster? (3:19)
- What are the limitations of this analysis and what future studies are planned? (4:35)
Disclosures: Gil Y Melmed has consulted for AbbVie, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol-Meyers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, Techlab, and has received research funding from Pfizer for an unrelated investigator-initiated study.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Stefan Schreiber, ECCO 2021: Risankizumab – an Induction Therapy for Crohn’s Disease
We were delighted to catch up with Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) to discuss the results from the phase 3 ADVANCE and MOTIVATE studies, investigating risankizumab as an induction therapy in patients with moderate-to-severe Crohn’s Disease. The abstract ‘Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results […]
Stefan Schreiber, ECCO 2021: Filgotinib for the Treatment of Ulcerative Colitis
TouchIMMUNOLOGY had the pleasure of talking to Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) around the efficacy and safety findings from the SELECTION study and its long term extension. The abstract ‘Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study.‘ (OP04) was […]
Eamonn Quigley, DDW 2021: Biotherapeutic Blautia Hydrogentrophica in IBS
It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS). His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!